Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 278.5 CHF -2.89% Market Closed
Market Cap: 225.4B CHF

EV/EBITDA
Enterprise Value to EBITDA

10.8
Current
10.3
Median
12.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
10.8
=
Enterprise Value
237.7B CHF
/
EBITDA
22B CHF
EBITDA Growth EV/EBITDA to Growth
CH
Roche Holding AG
SIX:ROG
Average EV/EBITDA: 396
10.8
8%
1.4
US
Eli Lilly and Co
NYSE:LLY
41.1
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.8
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
15%
0.9
UK
AstraZeneca PLC
LSE:AZN
127
9%
14.1
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.3
3%
2.8
FR
Sanofi SA
PAR:SAN
9.4
7%
1.3

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
10
2-Years Forward
EV/EBITDA
9.1
3-Years Forward
EV/EBITDA
8.7